The startup develops therapeutics aimed at enhancing ovarian function to extend the health span of women. By focusing on ovarian aging, the company engages in biomedical research and clinical development to provide targeted treatments that address the physiological changes associated with aging in women.
Funding
$11.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Women experience a decline in ovarian function with age, leading to adverse health outcomes, including increased risk of cardiovascular disease, loss of bone density, and declines in neurocognitive health. Current healthcare lacks targeted treatments addressing the physiological changes associated with ovarian aging, leaving a significant unmet need in women's health. The asynchronous aging of ovaries compared to other tissues puts women at a distinct disadvantage, impacting overall healthspan and longevity.
Solution
Oviva Therapeutics is developing first-in-class therapeutics designed to improve ovarian function and extend female healthspan by addressing the fundamental causal factors of ovarian aging. The company's approach focuses on preserving the ovarian reserve and mitigating the negative health consequences associated with menopause. Oviva's lead candidate, an enhanced form of human Anti-Müllerian Hormone (AMH), aims to modulate folliculogenesis at the earliest possible stage, impacting fertility treatment, contraception, and patients with diminished ovarian reserve or premature ovarian insufficiency. By intervening on the ovarian reserve, Oviva strives to delay the onset of menopause and improve overall healthspan in women as they age. The company is also engaging with scientists, clinicians, policy makers and the general public to elevate the conversation around women’s health.
Target Audience
The primary target audience includes women experiencing age-related decline in ovarian function, those seeking fertility treatments, and individuals with diminished ovarian reserve or premature ovarian insufficiency.
Features
- Development of therapeutics targeting the ovarian reserve to extend ovarian function.
- Focus on Anti-Müllerian Hormone (AMH) to regulate follicle development and egg quantity.
- Pre-clinical and clinical strategies to close knowledge gaps and seed continued innovation in ovarian health.
- Recombinant AMH program designed to intervene on the ovarian reserve.
- Therapeutic development for fertility treatment, contraception, and patients with diminished ovarian reserve or premature ovarian insufficiency.
- Modulation of folliculogenesis at the earliest possible stage.